Alzamend Neuro (NASDAQ:ALZN – Get Free Report) had its price objective reduced by Ascendiant Capital Markets from $32.00 to $20.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.
Alzamend Neuro Stock Down 1.8 %
Shares of ALZN opened at $0.68 on Monday. Alzamend Neuro has a 12-month low of $0.64 and a 12-month high of $15.06. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.36.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. As a group, sell-side analysts predict that Alzamend Neuro will post -1.68 EPS for the current year.
Hedge Funds Weigh In On Alzamend Neuro
Alzamend Neuro Company Profile
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
See Also
- Five stocks we like better than Alzamend Neuro
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- How to trade penny stocks: A step-by-step guide
- 3 Unique and Dominant Consumer Staples ETF Plays
- What Investors Need to Know About Upcoming IPOs
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.